Skip to content

Price / book at other companies

Amgen logo
AmgenAMGN
20.6×-6.3×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
2.6×+0.2×
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
3.2×+2.0×
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
4.8×+4.1×
Savara logo
SavaraSVRA
6.3×+3.1×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
125.1×+108×

Other financials

Income statement

See full
Revenue$1.0M+82.7%
Operating income-$43.6M-36.2%
Net income-$40.6M-48.8%
EPS (diluted)-$0.75-47.1%

Balance sheet

See full
Cash & equivalents$96.7M+35.6%
Total debt$1.1M-34.5%
Total equity$304.0M-31.8%
Total assets$318.1M-30.3%

Cash flow

See full
Operating cash flow-$47.9M-16.2%
CapEx$54.0K-70.8%
Free cash flow-$30.7M-55.0%

Valuation

See full
Market cap$346.11M-40.9%
Enterprise value$250.5M-51.4%
P/S104.2×-151×

Profitability

See full
Operating margin-5,176.5%+1,764pp
Net margin-4,719%+2,752pp

Returns & leverage

See full
Return on equity-41.8%
Debt / equity0.0×
Current ratio23.1×-24.3×

Where this comes from

Calculated from Upstream Bio, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Upstream Bio, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Upstream Bio, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Upstream Bio, Inc.'s price / book?
Upstream Bio, Inc. (UPB) reported price / book of 1.6× in Q1 2026.
How has Upstream Bio, Inc.'s price / book changed year-over-year?
Upstream Bio, Inc.'s price / book increased by 118.7% year-over-year, from 0.7× to 1.6×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.